Intellia Therapeutics (NTLA) Financials

$8.10 -0.21 (-2.47%)

Closing price 04/23/2025 03:58 PM Eastern

Extended Trading

$8.08 -0.03 (-0.31%)

As of 07:20 AM Eastern

Annual Income Statements for Intellia Therapeutics

This table shows Intellia Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Net Income / (Loss) Attributable to Common Shareholders	-474	-481	-519
Consolidated Net Income / (Loss)	-474	-481	-519
Net Income / (Loss) Continuing Operations	-474	-477	-518
Total Pre-Tax Income	-474	-477	-518
Total Operating Income	-458	-515	-534
Total Gross Profit	52	36	58
Total Revenue	52	36	58
Operating Revenue	52	36	58
Total Cost of Revenue	0.00	0.00	0.00
Total Operating Expenses	510	552	592
Selling, General & Admin Expense	90	116	126
Research & Development Expense	420	435	466
Other Special Charges / (Income)	-	0.10	0.00
Total Other Income / (Expense), net	-16	38	16
Interest & Investment Income	-2.54	34	15
Other Income / (Expense), net	-13	3.64	0.73
Basic Earnings per Share	($6.16)	($5.42)	($5.25)
Weighted Average Basic Shares Outstanding	76.97M	88.77M	98.85M
Diluted Earnings per Share	($6.16)	($5.42)	($5.25)
Weighted Average Diluted Shares Outstanding	76.97M	88.77M	98.85M
Weighted Average Basic & Diluted Shares Outstanding	88.02M	96.11M	103.52M

This table shows Intellia Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Income / (Loss) Attributable to Common Shareholders	-113	-113	-103	-124	-122	-132	-107	-147	-136	-129
Consolidated Net Income / (Loss)	-113	-113	-103	-124	-122	-132	-107	-147	-136	-129
Net Income / (Loss) Continuing Operations	-113	-113	-103	-125	-122	-128	-107	-147	-136	-128
Total Pre-Tax Income	-113	-113	-103	-125	-122	-128	-107	-147	-136	-128
Total Operating Income	-106	-110	-112	-132	-131	-140	-114	-139	-145	-136
Total Gross Profit	13	14	13	14	12	-1.92	29	6.96	9.11	13
Total Revenue	13	14	13	14	12	-1.92	29	6.96	9.11	13
Operating Revenue	13	14	13	14	12	-1.92	29	6.96	9.11	13
Total Operating Expenses	119	123	125	146	143	138	143	146	154	149
Selling, General & Admin Expense	22	24	27	31	29	29	31	32	31	32
Research & Development Expense	97	100	97	115	114	109	112	114	123	117
Total Other Income / (Expense), net	-7.70	-2.71	8.83	7.46	9.18	12	6.57	-8.14	9.06	8.49
Interest & Investment Income	0.11	2.11	8.93	8.65	8.88	7.73	6.57	-7.93	9.06	7.55
Other Income / (Expense), net	-7.81	-4.81	-0.10	-1.19	0.30	4.63	0.00	-0.21	0.00	0.94
Basic Earnings per Share	($1.49)	($1.38)	($1.17)	($1.40)	($1.38)	($1.47)	($1.12)	($1.52)	($1.34)	($1.27)
Weighted Average Basic Shares Outstanding	76.05M	76.97M	87.77M	88.19M	88.65M	88.77M	95.50M	96.98M	101.00M	98.85M
Diluted Earnings per Share	($1.49)	($1.38)	($1.17)	($1.40)	($1.38)	($1.47)	($1.12)	($1.52)	($1.34)	($1.27)
Weighted Average Diluted Shares Outstanding	76.05M	76.97M	87.77M	88.19M	88.65M	88.77M	95.50M	96.98M	101.00M	98.85M
Weighted Average Basic & Diluted Shares Outstanding	78.68M	88.02M	88.14M	88.49M	89.55M	96.11M	96.48M	101.58M	101.85M	103.52M

This table details how cash moves in and out of Intellia Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Net Change in Cash & Equivalents	410	-295	-38
Net Cash From Operating Activities	-333	-394	-349
Net Cash From Continuing Operating Activities	-333	-394	-349
Net Income / (Loss) Continuing Operations	-474	-481	-519
Consolidated Net Income / (Loss)	-474	-481	-519
Depreciation Expense	7.57	8.98	10
Amortization Expense	4.00	-26	-18
Non-Cash Adjustments To Reconcile Net Income	183	175	187
Changes in Operating Assets and Liabilities, net	-54	-71	-9.59
Net Cash From Investing Activities	160	-31	126
Net Cash From Continuing Investing Activities	160	-31	126
Purchase of Property, Plant & Equipment	-14	-14	-5.78
Acquisitions	-45	0.00	0.00
Purchase of Investments	-429	-904	-936
Sale of Property, Plant & Equipment	0.15	0.00	0.00
Sale and/or Maturity of Investments	648	887	1,067
Net Cash From Financing Activities	583	130	186
Net Cash From Continuing Financing Activities	583	130	186
Issuance of Common Equity	568	124	180
Other Financing Activities, net	15	6.60	5.86

This table details how cash moves in and out of Intellia Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Change in Cash & Equivalents	-6.91	386	-229	-122	-2.78	59	-55	-41	-10	69
Net Cash From Operating Activities	-79	-90	-109	-90	-101	-93	-121	-58	-85	-85
Net Cash From Continuing Operating Activities	-79	-90	-109	-90	-101	-93	-121	-58	-85	-85
Net Income / (Loss) Continuing Operations	-113	-113	-103	-124	-122	-132	-107	-147	-136	-129
Consolidated Net Income / (Loss)	-113	-113	-103	-124	-122	-132	-107	-147	-136	-129
Depreciation Expense	1.95	2.03	2.05	2.17	2.29	2.47	2.51	2.60	2.61	2.57
Amortization Expense	0.82	-1.25	-4.57	-7.10	-7.92	-6.31	-5.29	-4.65	-4.28	-3.60
Non-Cash Adjustments To Reconcile Net Income	33	35	38	48	45	45	24	66	48	49
Changes in Operating Assets and Liabilities, net	-0.98	-13	-41	-9.69	-18	-1.75	-35	25	4.86	-4.38
Net Cash From Investing Activities	48	-30	-122	-35	80	46	5.90	-24	-7.71	152
Net Cash From Continuing Investing Activities	48	-30	-122	-35	80	46	5.90	-24	-7.71	152
Purchase of Property, Plant & Equipment	-4.24	-3.91	-3.83	-4.30	-4.33	-1.52	-2.51	-1.01	-1.28	-0.98
Purchase of Investments	-161	-236	-382	-243	-129	-150	-260	-301	-206	-169
Sale and/or Maturity of Investments	213	210	264	213	213	197	268	278	200	322
Net Cash From Financing Activities	24	506	2.22	2.52	19	106	60	41	82	2.32
Net Cash From Continuing Financing Activities	24	506	2.22	2.52	19	106	60	41	82	2.32
Issuance of Common Equity	23	505	1.47	2.05	15	105	58	40	80	1.29
Other Financing Activities, net	0.72	0.53	0.76	0.47	4.38	1.00	1.96	1.18	1.70	1.03

This table presents Intellia Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Total Assets	1,520	1,301	1,191
Total Current Assets	1,217	998	640
Cash & Equivalents	524	227	189
Short-Term Investments	669	685	412
Accounts Receivable	3.77	36	8.52
Prepaid Expenses	20	50	30
Plant, Property, & Equipment, net	28	33	27
Total Noncurrent Assets	275	270	524
Long-Term Investments	142	155	304
Other Noncurrent Operating Assets	133	115	219
Total Liabilities & Shareholders' Equity	1,520	1,301	1,191
Total Liabilities	285	251	319
Total Current Liabilities	127	115	111
Accounts Payable	5.15	7.45	15
Accrued Expenses	61	67	55
Current Deferred Revenue	44	22	21
Other Current Liabilities	17	19	20
Total Noncurrent Liabilities	158	136	208
Noncurrent Deferred Revenue	20	39	18
Other Noncurrent Operating Liabilities	138	97	190
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	1,236	1,050	872
Total Preferred & Common Equity	1,236	1,050	872
Total Common Equity	1,236	1,050	872
Common Stock	2,420	2,711	3,049
Retained Earnings	-1,177	-1,658	-2,177
Accumulated Other Comprehensive Income / (Loss)	-7.46	-2.26	0.61

This table presents Intellia Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Total Assets	1,084	1,418	1,323	1,243	1,260	1,192	1,173
Total Current Assets	859	964	940	893	884	757	711
Cash & Equivalents	141	294	172	168	172	131	120
Short-Term Investments	687	639	736	687	619	560	538
Accounts Receivable	4.02	4.91	5.06	6.49	36	12	8.85
Prepaid Expenses	27	25	26	32	56	54	44
Plant, Property, & Equipment, net	27	32	33	34	32	30	29
Total Noncurrent Assets	199	423	350	316	343	404	434
Long-Term Investments	98	294	227	197	233	299	333
Other Noncurrent Operating Assets	101	128	124	119	110	105	100
Total Liabilities & Shareholders' Equity	1,084	1,418	1,323	1,243	1,260	1,192	1,173
Total Liabilities	260	227	218	206	223	220	211
Total Current Liabilities	131	103	100	92	98	105	106
Accounts Payable	4.38	6.89	12	3.55	14	19	13
Accrued Expenses	58	45	50	58	43	45	51
Current Deferred Revenue	55	35	22	13	22	22	22
Other Current Liabilities	14	16	17	17	19	19	19
Total Noncurrent Liabilities	128	124	119	114	126	115	105
Noncurrent Deferred Revenue	26	14	13	13	33	28	23
Other Noncurrent Operating Liabilities	103	110	106	101	92	87	82
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	825	1,191	1,105	1,037	1,036	971	963
Total Preferred & Common Equity	825	1,191	1,105	1,037	1,036	971	963
Total Common Equity	825	1,191	1,105	1,037	1,036	971	963
Common Stock	1,898	2,474	2,513	2,567	2,803	2,885	3,008
Retained Earnings	-1,064	-1,280	-1,404	-1,526	-1,766	-1,913	-2,049
Accumulated Other Comprehensive Income / (Loss)	-9.37	-2.68	-3.87	-3.57	-0.95	-1.16	3.30

This table displays calculated financial ratios and metrics derived from Intellia Therapeutics' official financial filings.

Metric	2022	2023	2024
Growth Metrics	-	-	-
Revenue Growth	57.69%	-30.40%	59.55%
EBITDA Growth	-80.05%	-14.89%	-2.36%
EBIT Growth	-74.67%	-8.48%	-4.28%
NOPAT Growth	-71.05%	-12.47%	-3.68%
Net Income Growth	-77.01%	-1.48%	-7.86%
EPS Growth	-62.96%	12.01%	3.14%
Operating Cash Flow Growth	-48.11%	-18.24%	11.47%
Free Cash Flow Firm Growth	-174.98%	-24.98%	19.61%
Invested Capital Growth	25.57%	83.33%	-105.47%
Revenue Q/Q Growth	1.40%	-29.92%	34.33%
EBITDA Q/Q Growth	-8.40%	-4.96%	0.85%
EBIT Q/Q Growth	-7.26%	-4.14%	0.34%
NOPAT Q/Q Growth	-6.92%	-6.14%	0.64%
Net Income Q/Q Growth	-7.28%	-4.06%	0.62%
EPS Q/Q Growth	-4.58%	-1.69%	3.67%
Operating Cash Flow Q/Q Growth	-11.82%	-0.81%	2.20%
Free Cash Flow Firm Q/Q Growth	-16.91%	-4.09%	1.57%
Invested Capital Q/Q Growth	1.50%	-13.04%	-17.97%
Profitability Metrics	-	-	-
Gross Margin	100.00%	100.00%	100.00%
EBITDA Margin	-882.70%	-1,457.14%	-934.85%
Operating Margin	-879.04%	-1,420.51%	-923.10%
EBIT Margin	-904.91%	-1,410.49%	-921.84%
Profit (Net Income) Margin	-909.78%	-1,326.51%	-896.77%
Tax Burden Percent	100.00%	100.78%	100.14%
Interest Burden Percent	100.54%	93.32%	97.14%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%
Return on Equity (ROE)	-41.67%	-42.10%	-54.00%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-33.51%	-36.27%	-42.82%
Return on Assets (ROA)	-33.70%	-34.11%	-41.66%
Return on Common Equity (ROCE)	-41.67%	-42.10%	-54.00%
Return on Equity Simple (ROE_SIMPLE)	-38.38%	-45.82%	-59.52%
Net Operating Profit after Tax (NOPAT)	-321	-361	-374
NOPAT Margin	-615.33%	-994.36%	-646.17%
Net Nonoperating Expense Percent (NNEP)	-12.24%	-10.03%	-14.70%
Return On Investment Capital (ROIC_SIMPLE)	-25.96%	-34.35%	-42.89%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	173.26%	321.15%	217.41%
R&D to Revenue	805.78%	1,199.36%	805.69%
Operating Expenses to Revenue	979.04%	1,520.79%	1,023.10%
Earnings before Interest and Taxes (EBIT)	-472	-512	-534
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-460	-529	-541
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	2.22	2.60	1.36
Price to Tangible Book Value (P/TBV)	2.22	2.60	1.36
Price to Revenue (P/Rev)	52.67	75.27	20.52
Price to Earnings (P/E)	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	27.06	45.87	4.86
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00
Financial Leverage	-1.10	-1.05	-1.03
Leverage Ratio	1.24	1.23	1.30
Compound Leverage Factor	1.24	1.15	1.26
Debt to Total Capital	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00
Altman Z-Score	4.58	4.29	-1.22
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	9.61	8.67	5.77
Quick Ratio	9.45	8.23	5.50
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-355	-443	-357
Operating Cash Flow to CapEx	-2,485.73%	-2,817.92%	-6,038.08%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00
Efficiency Ratios	-	-	-
Asset Turnover	0.04	0.03	0.05
Accounts Receivable Turnover	17.98	1.80	2.57
Inventory Turnover	0.00	0.00	0.00
Fixed Asset Turnover	2.13	1.20	1.92
Accounts Payable Turnover	0.00	0.00	0.00
Days Sales Outstanding (DSO)	20.31	202.37	141.81
Days Inventory Outstanding (DIO)	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	20.31	202.37	141.81
Capital & Investment Metrics	-	-	-
Invested Capital	-99	-17	-34
Invested Capital Turnover	-0.45	-0.63	-2.29
Increase / (Decrease) in Invested Capital	34	83	-17
Enterprise Value (EV)	1,410	1,664	282
Market Capitalization	2,745	2,731	1,188
Book Value per Share	$15.70	$11.73	$8.56
Tangible Book Value per Share	$15.70	$11.73	$8.56
Total Capital	1,236	1,050	872
Total Debt	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00
Net Debt	-1,335	-1,067	-906
Capital Expenditures (CapEx)	13	14	5.78
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-102	-29	-73
Debt-free Net Working Capital (DFNWC)	1,090	883	529
Net Working Capital (NWC)	1,090	883	529
Net Nonoperating Expense (NNE)	153	120	145
Net Nonoperating Obligations (NNO)	-1,335	-1,067	-906
Total Depreciation and Amortization (D&A)	12	-17	-7.53
Debt-free, Cash-free Net Working Capital to Revenue	-196.43%	-80.22%	-125.27%
Debt-free Net Working Capital to Revenue	2,091.75%	2,434.52%	914.03%
Net Working Capital to Revenue	2,091.75%	2,434.52%	914.03%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($6.16)	($5.42)	($5.25)
Adjusted Weighted Average Basic Shares Outstanding	76.97M	88.77M	98.85M
Adjusted Diluted Earnings per Share	($6.16)	($5.42)	($5.25)
Adjusted Weighted Average Diluted Shares Outstanding	76.97M	88.77M	98.85M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	88.02M	96.11M	103.52M
Normalized Net Operating Profit after Tax (NOPAT)	-321	-361	-374
Normalized NOPAT Margin	-615.33%	-994.17%	-646.17%
Pre Tax Income Margin	-909.78%	-1,316.22%	-895.50%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Intellia Therapeutics' official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	84.15%	5.59%	12.03%	-3.11%	-9.60%	-114.12%	129.53%	-48.82%	-24.02%	771.57%
EBITDA Growth	-62.80%	-45.43%	18.37%	-45.70%	-23.41%	-21.89%	-1.92%	-2.06%	-7.33%	1.84%
EBIT Growth	-57.84%	-38.47%	22.48%	-35.06%	-15.41%	-17.72%	-1.74%	-4.29%	-10.67%	-0.18%
NOPAT Growth	-46.58%	-36.90%	22.38%	-34.62%	-24.24%	-27.07%	-1.83%	-5.07%	-10.42%	2.46%
Net Income Growth	-58.04%	-39.60%	29.79%	-22.85%	-7.94%	-16.54%	-4.18%	-18.83%	-11.04%	2.47%
EPS Growth	-53.61%	-24.32%	40.31%	-5.26%	7.38%	-6.52%	4.27%	-8.57%	2.90%	13.61%
Operating Cash Flow Growth	-20.77%	-64.44%	-37.00%	-6.15%	-29.11%	-3.54%	-10.37%	35.58%	16.32%	8.45%
Free Cash Flow Firm Growth	-219.23%	-5,256.36%	-526.44%	-959.35%	-129.78%	-62.52%	24.36%	36.64%	51.04%	56.82%
Invested Capital Growth	3.44%	25.57%	71.23%	72.43%	85.47%	83.33%	131.84%	37.99%	-96.89%	-105.47%
Revenue Q/Q Growth	-5.45%	2.31%	-7.12%	7.84%	-11.78%	-115.99%	1,609.39%	-75.96%	30.96%	41.30%
EBITDA Q/Q Growth	-16.36%	-3.21%	-0.40%	-20.83%	1.45%	-1.95%	17.20%	-21.00%	-3.64%	6.76%
EBIT Q/Q Growth	-14.65%	-1.38%	2.47%	-19.16%	2.03%	-3.40%	16.90%	-22.15%	-3.96%	6.40%
NOPAT Q/Q Growth	-7.35%	-4.32%	-1.70%	-18.20%	0.93%	-6.70%	18.51%	-21.96%	-4.12%	5.75%
Net Income Q/Q Growth	-12.47%	-0.16%	9.07%	-19.93%	1.18%	-8.13%	18.71%	-36.80%	7.66%	5.02%
EPS Q/Q Growth	-12.03%	7.38%	15.22%	-19.66%	1.43%	-6.52%	23.81%	-35.71%	11.84%	5.22%
Operating Cash Flow Q/Q Growth	7.72%	-14.44%	-21.65%	17.38%	-12.24%	8.21%	-29.67%	51.78%	-45.80%	-0.42%
Free Cash Flow Firm Q/Q Growth	-378.07%	-43.55%	-52.95%	-0.92%	-3.70%	-1.53%	28.81%	15.46%	19.87%	10.44%
Invested Capital Q/Q Growth	7.53%	1.50%	62.71%	18.84%	51.26%	-13.04%	171.21%	-258.07%	-54.75%	-17.97%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	0.00%	100.00%	100.00%	100.00%	100.00%
EBITDA Margin	-833.45%	-840.77%	-908.92%	-1,018.46%	-1,137.79%	0.00%	-403.58%	-2,031.06%	-1,607.32%	-1,060.62%
Operating Margin	-795.49%	-811.07%	-888.13%	-973.47%	-1,093.29%	0.00%	-394.00%	-1,998.61%	-1,588.96%	-1,059.86%
EBIT Margin	-854.36%	-846.53%	-888.93%	-982.23%	-1,090.82%	0.00%	-394.00%	-2,001.60%	-1,588.96%	-1,052.57%
Profit (Net Income) Margin	-853.53%	-835.53%	-818.07%	-909.82%	-1,019.21%	0.00%	-371.30%	-2,112.62%	-1,489.54%	-1,001.23%
Tax Burden Percent	100.00%	100.54%	100.00%	99.05%	100.24%	103.63%	100.00%	99.86%	100.00%	100.73%
Interest Burden Percent	99.90%	98.17%	92.03%	93.52%	93.21%	94.28%	94.24%	105.70%	93.74%	94.43%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-45.76%	-41.67%	-40.14%	-45.68%	-49.66%	-42.10%	-43.60%	-49.02%	-52.23%	-54.00%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-3,484.04%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-36.30%	-31.35%	-36.28%	-42.81%	-48.51%	0.00%	-15.48%	-73.17%	-56.66%	-48.89%
Return on Assets (ROA)	-36.27%	-30.95%	-33.39%	-39.66%	-45.33%	0.00%	-14.59%	-77.23%	-53.11%	-46.51%
Return on Common Equity (ROCE)	-45.76%	-41.67%	-40.14%	-45.68%	-49.66%	-42.10%	-43.60%	-49.02%	-52.23%	-54.00%
Return on Equity Simple (ROE_SIMPLE)	-53.58%	0.00%	-36.15%	-41.04%	-44.58%	0.00%	-46.86%	-52.40%	-54.26%	0.00%
Net Operating Profit after Tax (NOPAT)	-74	-77	-78	-93	-92	-98	-80	-97	-101	-96
NOPAT Margin	-556.84%	-567.75%	-621.69%	-681.43%	-765.30%	0.00%	-275.80%	-1,399.02%	-1,112.27%	-741.91%
Net Nonoperating Expense Percent (NNEP)	-3.68%	-2.90%	-2.14%	-2.92%	-3.08%	-2.85%	-2.45%	-4.67%	-3.36%	-3.38%
Return On Investment Capital (ROIC_SIMPLE)	-	-6.24%	-	-	-	-9.32%	-	-	-	-10.95%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	166.93%	174.07%	217.74%	225.48%	245.19%	0.00%	107.45%	456.99%	334.77%	252.01%
R&D to Revenue	728.56%	737.01%	770.40%	847.99%	948.10%	0.00%	386.55%	1,641.61%	1,354.19%	907.85%
Operating Expenses to Revenue	895.49%	909.24%	988.13%	1,073.47%	1,193.29%	0.00%	494.00%	2,098.61%	1,688.96%	1,159.86%
Earnings before Interest and Taxes (EBIT)	-113	-115	-112	-134	-131	-135	-114	-139	-145	-136
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-111	-114	-115	-138	-136	-139	-117	-141	-146	-137
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	5.16	2.22	2.75	3.25	2.70	2.60	2.38	2.22	2.17	1.36
Price to Tangible Book Value (P/TBV)	5.16	2.22	2.75	3.25	2.70	2.60	2.38	2.22	2.17	1.36
Price to Revenue (P/Rev)	82.75	52.67	61.35	67.77	54.05	75.27	46.83	46.97	48.45	20.52
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	122.02	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	64.74	27.06	38.38	46.37	33.73	45.87	27.36	25.44	25.44	4.86
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-1.11	-1.10	-1.08	-1.07	-1.06	-1.05	-1.01	-1.02	-1.02	-1.03
Leverage Ratio	1.25	1.24	1.22	1.23	1.25	1.23	1.20	1.21	1.21	1.30
Compound Leverage Factor	1.25	1.21	1.12	1.15	1.17	1.16	1.13	1.28	1.13	1.22
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	8.97	5.35	7.91	8.86	6.90	5.25	5.14	3.94	3.75	-0.12
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	6.55	9.61	9.32	9.41	9.72	8.67	9.03	7.21	6.73	5.77
Quick Ratio	6.35	9.45	9.08	9.14	9.37	8.23	8.45	6.69	6.31	5.50
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-77	-111	-170	-172	-178	-181	-129	-109	-87	-78
Operating Cash Flow to CapEx	-1,853.34%	-2,297.26%	-2,853.03%	-2,100.05%	-2,340.28%	-6,121.97%	-4,814.92%	-5,749.60%	-6,633.07%	-8,684.51%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.04	0.04	0.04	0.04	0.04	0.03	0.04	0.04	0.04	0.05
Accounts Receivable Turnover	15.78	17.98	15.95	13.41	9.85	1.80	2.55	5.29	5.62	2.57
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	2.21	2.13	1.93	1.80	1.71	1.20	1.65	1.45	1.38	1.92
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	23.13	20.31	22.89	27.22	37.07	202.37	143.40	69.02	65.00	141.81
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	23.13	20.31	22.89	27.22	37.07	202.37	143.40	69.02	65.00	141.81
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	-101	-99	-37	-30	-15	-17	12	-19	-29	-34
Invested Capital Turnover	-0.50	-0.45	-0.65	-0.76	-0.90	-0.63	-4.17	-1.89	-1.98	-2.29
Increase / (Decrease) in Invested Capital	3.59	34	92	79	86	83	49	11	-14	-17
Enterprise Value (EV)	3,328	1,410	2,053	2,459	1,746	1,664	1,439	1,169	1,096	282
Market Capitalization	4,254	2,745	3,280	3,594	2,798	2,731	2,464	2,159	2,087	1,188
Book Value per Share	$10.85	$15.70	$13.53	$12.54	$11.72	$11.73	$10.85	$10.07	$9.48	$8.56
Tangible Book Value per Share	$10.85	$15.70	$13.53	$12.54	$11.72	$11.73	$10.85	$10.07	$9.48	$8.56
Total Capital	825	1,236	1,191	1,105	1,037	1,050	1,036	971	963	872
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-926	-1,335	-1,228	-1,135	-1,052	-1,067	-1,024	-990	-991	-906
Capital Expenditures (CapEx)	4.24	3.91	3.83	4.30	4.33	1.52	2.51	1.01	1.28	0.98
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-100	-102	-73	-68	-53	-29	-5.16	-39	-53	-73
Debt-free Net Working Capital (DFNWC)	728	1,090	860	840	802	883	786	652	605	529
Net Working Capital (NWC)	728	1,090	860	840	802	883	786	652	605	529
Net Nonoperating Expense (NNE)	39	36	25	31	30	34	28	50	34	33
Net Nonoperating Obligations (NNO)	-926	-1,335	-1,228	-1,135	-1,052	-1,067	-1,024	-990	-991	-906
Total Depreciation and Amortization (D&A)	2.77	0.78	-2.52	-4.93	-5.63	-3.84	-2.77	-2.05	-1.67	-1.04
Debt-free, Cash-free Net Working Capital to Revenue	-195.28%	-196.43%	-136.99%	-128.79%	-102.86%	-80.22%	-9.81%	-84.73%	-122.77%	-125.27%
Debt-free Net Working Capital to Revenue	1,415.93%	2,091.75%	1,608.77%	1,583.30%	1,548.42%	2,434.52%	1,494.43%	1,418.67%	1,404.68%	914.03%
Net Working Capital to Revenue	1,415.93%	2,091.75%	1,608.77%	1,583.30%	1,548.42%	2,434.52%	1,494.43%	1,418.67%	1,404.68%	914.03%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($1.49)	($1.38)	($1.17)	($1.40)	($1.38)	($1.47)	($1.12)	($1.52)	($1.34)	($1.27)
Adjusted Weighted Average Basic Shares Outstanding	76.05M	76.97M	87.77M	88.19M	88.65M	88.77M	95.50M	96.98M	101.00M	98.85M
Adjusted Diluted Earnings per Share	($1.49)	($1.38)	($1.17)	($1.40)	($1.38)	($1.47)	($1.12)	($1.52)	($1.34)	($1.27)
Adjusted Weighted Average Diluted Shares Outstanding	76.05M	76.97M	87.77M	88.19M	88.65M	88.77M	95.50M	96.98M	101.00M	98.85M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	78.68M	88.02M	88.14M	88.49M	89.55M	96.11M	96.48M	101.58M	101.85M	103.52M
Normalized Net Operating Profit after Tax (NOPAT)	-74	-77	-78	-93	-92	-98	-80	-97	-101	-96
Normalized NOPAT Margin	-556.84%	-567.75%	-621.69%	-681.43%	-765.30%	0.00%	-275.80%	-1,399.02%	-1,112.27%	-741.91%
Pre Tax Income Margin	-853.53%	-831.02%	-818.07%	-918.57%	-1,016.74%	0.00%	-371.30%	-2,115.61%	-1,489.54%	-993.93%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Intellia Therapeutics' Financials

When does Intellia Therapeutics's financial year end?

According to the most recent income statement we have on file, Intellia Therapeutics' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Intellia Therapeutics' net income changed over the last 2 years?

Intellia Therapeutics' net income appears to be on an upward trend, with a most recent value of -$519.02 million in 2024, rising from -$474.19 million in 2022. The previous period was -$481.19 million in 2023.

What is Intellia Therapeutics's operating income?

Intellia Therapeutics's total operating income in 2024 was -$534.26 million, based on the following breakdown:

Total Gross Profit: $57.88 million
Total Operating Expenses: $592.14 million

How has Intellia Therapeutics revenue changed over the last 2 years?

Over the last 2 years, Intellia Therapeutics' total revenue changed from $52.12 million in 2022 to $57.88 million in 2024, a change of 11.0%.

How much debt does Intellia Therapeutics have?

Intellia Therapeutics' total liabilities were at $319.06 million at the end of 2024, a 27.2% increase from 2023, and a 12.1% increase since 2022.

How much cash does Intellia Therapeutics have?

In the past 2 years, Intellia Therapeutics' cash and equivalents has ranged from $189.18 million in 2024 to $523.51 million in 2022, and is currently $189.18 million as of their latest financial filing in 2024.

How has Intellia Therapeutics' book value per share changed over the last 2 years?

Over the last 2 years, Intellia Therapeutics' book value per share changed from 15.70 in 2022 to 8.56 in 2024, a change of -45.5%.

Related Companies

This page (NASDAQ:NTLA) was last updated on 4/24/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Intellia Therapeutics (NTLA) Financials

Frequently Asked Questions About Intellia Therapeutics' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Intellia Therapeutics (NTLA) Financials

Annual Income Statements for Intellia Therapeutics

Quarterly Income Statements for Intellia Therapeutics

Annual Cash Flow Statements for Intellia Therapeutics

Quarterly Cash Flow Statements for Intellia Therapeutics

Annual Balance Sheets for Intellia Therapeutics

Quarterly Balance Sheets for Intellia Therapeutics

Annual Metrics and Ratios for Intellia Therapeutics

Quarterly Metrics and Ratios for Intellia Therapeutics

Frequently Asked Questions About Intellia Therapeutics' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools